Investor Relations

Poised for substantial growth from
long-read DNA sequencing

RevoluGen is a privately held company, funded since 2016 by HNW investors committed to its mission of commercialising its products and technologies to advance applications in the field of DNA sequencing.

The company has evolved from an R&D-focused organization to an ambitious and agile organisation focused on rapid commercialization. It has established partnerships for manufacturing, logistics, global customer access, production at scale and automation, with world-leading molecular biology tools companies, and is now open to investment with which to further accelerate its growth in support of the explosive opportunities in long-read DNA sequencing.

Investment Highlights

Poised for substantial growth through commercial global distribution and manufacturing agreements with Merck KGaA and Cytiva

Disruptive, cutting edge Fire Monkey technology to extract longer and purer DNA than existing methods

Only technology that allows extraction and simultaneous size selection of long-length DNA fragments, which are critical for long-read DNA sequencing

Superior efficacy and accuracy validated on various sequencing platforms such as Oxford Nanopore, 10x Genomics, Illumina and PacBio

Automated protocol in development to enhance throughput and efficiency in order to reduce costs

Multiple growth and expansion opportunities in infectious diseases, Antibiotic Microbial Resistance (AMR) and microbiome metagenomics

RevoluGen featured in the ‘Biology Impacting Lives’ programme from ITN Productions in partnership with the Royal Society of Biology | October 2020